- Home
- MIST vs NSPR Comparison
MIST vs NSPR Comparison
Compare MIST & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIST
- NSPR
- Stock Information
- Founded
- MIST 2003
- NSPR 2005
- Country
- MIST Canada
- NSPR United States
- Employees
- MIST N/A
- NSPR N/A
- Industry
- MIST Biotechnology: Pharmaceutical Preparations
- NSPR Medical/Dental Instruments
- Sector
- MIST Health Care
- NSPR Health Care
- Exchange
- MIST Nasdaq
- NSPR Nasdaq
- Market Cap
- MIST 89.8M
- NSPR 75.1M
- IPO Year
- MIST N/A
- NSPR N/A
- Fundamental
- Price
- MIST $1.71
- NSPR $2.44
- Analyst Decision
- MIST Strong Buy
- NSPR Strong Buy
- Analyst Count
- MIST 2
- NSPR 2
- Target Price
- MIST $7.50
- NSPR $4.50
- AVG Volume (30 Days)
- MIST 658.4K
- NSPR 44.5K
- Earning Date
- MIST 08-07-2025
- NSPR 08-05-2025
- Dividend Yield
- MIST N/A
- NSPR N/A
- EPS Growth
- MIST N/A
- NSPR N/A
- EPS
- MIST N/A
- NSPR N/A
- Revenue
- MIST N/A
- NSPR $7,027,000.00
- Revenue This Year
- MIST N/A
- NSPR $27.41
- Revenue Next Year
- MIST N/A
- NSPR $127.08
- P/E Ratio
- MIST N/A
- NSPR N/A
- Revenue Growth
- MIST N/A
- NSPR 8.49
- 52 Week Low
- MIST $0.63
- NSPR $2.07
- 52 Week High
- MIST $2.75
- NSPR $3.80
- Technical
- Relative Strength Index (RSI)
- MIST 60.15
- NSPR 50.84
- Support Level
- MIST $1.67
- NSPR $2.40
- Resistance Level
- MIST $1.80
- NSPR $2.59
- Average True Range (ATR)
- MIST 0.08
- NSPR 0.11
- MACD
- MIST -0.01
- NSPR 0.00
- Stochastic Oscillator
- MIST 43.24
- NSPR 57.50
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).
About NSPR InspireMD Inc.
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.